Business
JZZ Technologies, Inc. Joins with GenBio, Inc., Nutrific, and NutraEdge Biosciences Corp. to Create New Bioscience Products Company Focused on Breakthrough Therapeutic Products and Research
JZZ Technologies, Inc. Joins with GenBio, Inc., Nutrific, and NutraEdge Biosciences Corp. to Create New Bioscience Products Company Focused on Breakthrough Therapeutic Products and Research.
About this update from Ideal Group Of Companies Inc.
[{"type":"text","content":"JZZ Technologies, Inc. (OTC Pink: JZZI) has signed a Letter Of Intent (LOI) to join with biotech company GenBio, Inc., and bioscience company Nutrific of Aliso Viejo, California, to create a new business venture in the Life Extension and Longevity sector. The new entity, which will operate under the NutraEdge Biosciences Corp. brand, contemplates utilizing product development, research, and existing human resources of GenBio, Inc., and Nutrific in its pursuit of therapeutics for various medical ailments and age-related health issues.Under the terms, JZZ Technologies, Inc. will acquire 100% ownership of NutraEdge Biosciences Corp. GenBio Inc. and Nutrific are focused on rapidly developing a new range of natural extracts to enhance health. GenBio CSO, Professor Lindsay Brown, a former Professor of Biomedical Sciences, University of Southern Queensland, Australia, leads the research of the company's formulations and products.Professor Brown is a Fellow of the International Academy of Cardiovascular Science with 35 years of scientific research that encompasses an emphasis on drugs acting on the heart and associated Rific blood vessels and endocrine organs.GenBio CEO Giles Tilley has been involved with and directed international research into rare extracts since 2010 and initially worked alongside the pioneering investigational scientific teams who made a major medical breakthrough with a natural extract. He then amassed further worldwide research with other scientific teams who were also investigating specific properties for the same new, disruptive molecular platforms for pain relief, anti-inflammation, and age-related health issues.In 2014, Mr. Tilley was the first person to bring the rare extract to the United States for further phytochemical research. The subsequent medical findings, which have global implications for medication, make it imperative to take the research through an Investigational New Drug (IND) Program and into licensing. GenBio, Inc. intends to be the first company in the world to isolate and fractionate core molecules based on its remarkable findings.Nutrific continues to refine an entirely new range of never seen before nutraceuticals for various medical ailments, immune boost, and human life extension in this area.The venture between JZZ Technologies, Inc. and NutraEdge Bioscience Corp. will focus on th...